Entero Therapeutics : Corporate Fact Sheet (Entero Therapeutics Q224 Factsheet 2024.6.7 ADA Compliant 1)

Q2 2024

NASDAQ: ENTO

Targeted Therapies for Gastrointestinal Diseases

Corporate Overview

Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

The company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5- HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Clinical Pipeline

Product/Indication

LATIGLUTENASE

Celiac Disease

CAPESEROD

Gastroparesis

ADRULIPASE

Exocrine Pancreatic Insufficiency Monotherapy

Exocrine Pancreatic Insufficiency Combination w/ PERT

Technologies

Latiglutenase

Pre-IND

Phase 1

Phase 2

Phase 3

Phase 3 Ready

Phase 2 Anticipated

Phase 2b Completed

Phase 2a Completed

CapeserodAdrulipase

Orally administered, Phase 3 ready, recombinant digestive enzyme therapy to treat celiac disease

• Acquired from ImmunogenX in Mar. 2024
• Demonstrated effectiveness in alleviating symptoms of celiac disease in two Phase 2 trials

Re-purposed selective 5-HT4 receptor partial agonist for gastrointestinal indications

• In-licensedfrom Sanofi in Sept. 2023
• Unique mechanism of action applicable to several GI indications
• • Gastroparesis
  • Pediatric Ulcerative Colitis
  • Constipation

Recombinant lipase enzyme administered as an oral, non- systemic biologic capsule for the treatment of EPI

• Non-porcinerecombinant alternative
• Designed as a potential improvement over PERT
• • PERT can require upwards of 40 pills per day

www.enterothera.com

Entero Therapeutics, Inc. - 777 Yamato Road, Suite 502, Boca Raton, FL 33431

Q2 2024	NASDAQ: ENTO

Targeted Therapies for Gastrointestinal Diseases

Therapeutic Indications

Celiac Disease

• Celiac disease (CeD) is an autoimmune disorder of the small intestine resulting from intolerance to gluten proteins, afflicting nearly 1% of most population (~3.3 million patients in the U.S.)
• The principal physiology is villous atrophy in the small intestinal epithelium triggered by the ingestion of cereal grains, such as wheat, rye, or barley
• CeD has no known cure and the only effective therapy is adherence to a lifelong gluten-free diet

Gastroparesis

• Gastroparesis is the delayed movement of food from the stomach to the small intestine, not caused by blockage. Symptoms include feeling full soon after starting a meal or long after completing one, as well as nausea, and vomiting.
• Gastroparesis impacts approximately 50 in 100,000 people and is more common in women

Exocrine Pancreatic Insufficiency (EPI) in Cystic Fibrosis

• EPI affects 40,000 cystic fibrosis patients and 95,000 chronic pancreatitis patients in the U.S.
• High daily PERT pill burden with CF patients currently taking 25 to 40 capsules daily to control symptoms; safety concerns with black box warnings for PERT therapy (risks of fibrosing colonopathy and transmission of animal pathogens)

Clinical Development Plans & Milestones

Product	Indication	2023	2024	2025	2026	2027
Latiglutenase	Celiac disease				Phase 3 Dosing	Phase 3	BLA
			Safety

Capeserod

Gastroparesis

Phase 2*

Adrulipase

EPI in CF, CP

Phase 2b

*Subject to FDA IND review

Executive Management Team	Investor / Media Contacts
		[e-mail]
James Sapirstein	Chairman and CEO
		Russo Partners
Jack Syage, Ph.D.	President and CSO	David Schull/Liz Phillips (media)
Sarah Romano	Chief Financial Officer	[phone]
[e-mail]
Martin Krusin	SVP, Corporate Development	[e-mail]

www.enterothera.com

Entero Therapeutics, Inc. - 777 Yamato Road, Suite 502, Boca Raton, FL 33431